Ishita Drugs & Industries Ltd
Ishita Drugs & Industries Ltd (ISHITADR) last reported results for the quarter ended Jun 2026, with sales of ₹3.15 crore and net profit of ₹0.23 crore. Ishita Drugs & Industries Ltd’s board meets on 30 Oct 2026. The stock last traded at ₹79.8, a market capitalisation of ₹23.9 crore, on a P/E of 33.6. Over the past 52 weeks the stock has ranged between ₹66 and ₹90.8. Figures are as of 6 Oct 2026 and are not real time.
Ishita Drugs & Industries Ltd share price and key metrics
- Current price
- ₹79.8
- Market cap
- ₹23.9 cr
- Stock P/E
- 33.6
- Book value
- ₹38.7
- ROE
- 6.98%
- ROCE
- 8.66%
- Dividend yield
- 0.00%
- 52w high / low
- 90.8/66.0
Metrics as of 6 Oct 2026. Not real time.
Track Ishita Drugs & Industries Ltd
Cruxal reads every Ishita Drugs & Industries Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Ishita Drugs & Industries Ltd growth and returns
- 10 Years
- 8%
- 5 Years
- 1%
- 3 Years
- 7%
- TTM
- -28%
- 10 Years
- 19%
- 5 Years
- -1%
- 3 Years
- 10%
- TTM
- -30%
- 10 Years
- 20%
- 5 Years
- 11%
- 3 Years
- 4%
- 1 Year
- 6%
- 10 Years
- 7%
- 5 Years
- 8%
- 3 Years
- 8%
- Last Year
- 7%
Ishita Drugs & Industries Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹3.15 cr, down 41.7% from ₹5.4 cr a year earlier. Net profit was ₹0.23 cr, down 23.3% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 3.27 | 4.13 | 4.56 | 5.4 | 3.07 | 3.14 | 3.06 | 3.15 |
| Expenses | 3.03 | 3.83 | 4.27 | 5.06 | 2.89 | 3 | 2.96 | 2.84 |
| Operating profit | 0.24 | 0.3 | 0.29 | 0.34 | 0.18 | 0.14 | 0.1 | 0.31 |
| OPM % | 7.34% | 7.26% | 6.36% | 6.30% | 5.86% | 4.46% | 3.27% | 9.84% |
| Other income | 0.05 | 0.07 | 0.16 | 0.09 | 0.07 | 0.1 | 0.22 | 0.04 |
| Interest | 0 | 0.02 | 0.04 | 0.02 | 0 | 0.02 | 0.02 | 0 |
| Depreciation | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | 0.05 |
| Profit before tax | 0.26 | 0.32 | 0.38 | 0.38 | 0.22 | 0.19 | 0.28 | 0.3 |
| Tax % | 23.08% | 25.00% | 23.68% | 23.68% | 36.36% | 21.05% | 35.71% | 23.33% |
| Net profit | 0.19 | 0.24 | 0.29 | 0.3 | 0.14 | 0.16 | 0.18 | 0.23 |
| EPS (₹) | 0.64 | 0.80 | 0.97 | 1.00 | 0.47 | 0.54 | 0.60 | 0.77 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Ishita Drugs & Industries Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6.44 | 6.9 | 9.09 | 14.83 | 13.95 | 14.09 | 12.07 | 15.19 | 15 | 14.66 | 12.42 |
| Operating profit | 0.36 | 0.45 | 0.52 | 0.76 | 0.92 | 1.08 | 0.76 | 0.91 | 0.99 | 0.77 | 0.73 |
| OPM % | 5.59% | 6.52% | 5.72% | 5.12% | 6.59% | 7.67% | 6.30% | 5.99% | 6.60% | 5.25% | 5.88% |
| Net profit | 0.18 | 0.25 | 0.35 | 0.55 | 0.83 | 0.8 | 0.58 | 0.75 | 0.87 | 0.78 | 0.71 |
| EPS (₹) | 0.60 | 0.84 | 1.17 | 1.84 | 2.78 | 2.68 | 1.94 | 2.51 | 2.91 | 2.61 | 2.38 |
TTM is the trailing twelve months to the most recent quarter.
Ishita Drugs & Industries Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 |
| Reserves | 2.82 | 3.07 | 3.42 | 3.97 | 4.80 | 5.61 | 6.18 | 6.93 | 7.80 | 8.58 |
| Borrowings | 0.01 | 0.13 | 0.20 | 0.29 | 0.04 | 0.00 | 0.96 | 0.00 | 3.90 | 0.08 |
| Other liabilities | 1.37 | 0.97 | 1.73 | 2.30 | 1.43 | 2.66 | 1.27 | 0.89 | 1.60 | 0.95 |
| Total liabilities | 7.19 | 7.16 | 8.34 | 9.55 | 9.26 | 11.26 | 11.40 | 10.81 | 16.29 | 12.60 |
| Fixed assets | 1.02 | 1.19 | 1.30 | 1.14 | 1.00 | 0.88 | 0.89 | 0.80 | 0.88 | 0.88 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.75 |
| Investments | 2.70 | 3.15 | 4.04 | 5.29 | 3.11 | 4.06 | 3.39 | 3.34 | 3.87 | 4.45 |
| Other assets | 3.47 | 2.82 | 3.00 | 3.12 | 5.15 | 6.32 | 7.12 | 6.67 | 11.54 | 5.52 |
| Total assets | 7.19 | 7.16 | 8.34 | 9.55 | 9.26 | 11.26 | 11.40 | 10.81 | 16.29 | 12.60 |
As reported by the company. Total assets equal total liabilities by construction.
Ishita Drugs & Industries Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 0.52 | 0.72 | 0.79 | 1.05 | -0.67 | 3.08 | -2.90 | 2.12 | -3.64 | 3.92 |
| Cash from investing | -0.55 | -0.69 | -1.06 | -1.15 | 2.45 | -0.93 | 0.59 | 0.13 | -0.67 | -2.24 |
| Cash from financing | -1.05 | 0.05 | 0.09 | 0.09 | -0.24 | 0.00 | 1.05 | -0.87 | 4.33 | -3.81 |
| Net cash flow | -1.08 | 0.08 | -0.19 | -0.01 | 1.54 | 2.14 | -1.25 | 1.38 | 0.02 | -2.13 |
| Free cash flow | 0.48 | 0.41 | 0.52 | 1.04 | -0.67 | 3.06 | -3.03 | 2.09 | -3.82 | 2.07 |
| CFO / operating profit | 144% | 160% | 152% | 138% | -73% | 285% | -382% | 233% | -368% | 509% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Ishita Drugs & Industries Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 4.77% | 7.16% | 8.12% | 10.68% | 14.32% | 12.90% | 8.86% | 10.77% | 9.91% | 8.66% |
| Debtor days | 96.35 | 43.38 | 47.38 | 32.24 | 39.77 | 13.99 | 54.43 | 16.82 | 46.23 | 25.15 |
| Inventory days | 51.49 | 55.56 | 42.20 | 18.49 | 23.06 | 34.81 | 68.22 | 34.27 | 149.21 | 32.57 |
| Days payable | 108.49 | 43.21 | 78.70 | 60.25 | 34.76 | 73.22 | 36.67 | 14.87 | 31.78 | 19.83 |
| Cash conversion cycle | 39.35 | 55.72 | 10.88 | -9.52 | 28.07 | -24.41 | 85.99 | 36.22 | 163.66 | 37.89 |
| Working capital days | 56.68 | 32.27 | 8.03 | -10.83 | 29.83 | -27.46 | 42.94 | 21.87 | 30.17 | 43.82 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Ishita Drugs & Industries Ltd shareholding pattern
Promoters held 50.04% at Jun 2026, broadly unchanged since Jun 2025.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 49.80% | 49.85% | 49.91% | 49.92% | 49.96% | 50.04% | 50.04% | 50.04% |
| Public | 50.19% | 50.14% | 50.08% | 50.09% | 50.04% | 49.95% | 49.97% | 49.96% |
| No. of shareholders | 5,555 | 5,412 | 5,398 | 5,341 | 5,320 | 5,263 | 5,194 | 5,146 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When does Ishita Drugs & Industries Ltd’s board next meet?
Ishita Drugs & Industries Ltd’s board meets on 30 Oct 2026.
- Board meetingReappointment of Statutory Auditors for FY 2026-27
See the full results calendar for every Indian company reporting in the next 30 days.
Ishita Drugs & Industries Ltd corporate filings
- Ishita Drugs & Industries Ltd. reappoints Mrs. Abha Agrawal as Non-Executive Non-Independent Director post attaining age 75; also reappoints M/s. Jaymin Shah & Associates as statutory auditors for next yearCompany Updatelow impact
Cruxal's analysis: Ishita Drugs & Industries Ltd. announced the reappointment of Mrs. Abha Agrawal as a…
Read the full analysis - Shita Drugs & Industries Ltd. Appoints New Statutory Auditors for FY 2026-27Company Updatelow impact
Cruxal's analysis: Shita Drugs & Industries Ltd. has announced the appointment of M/s. Jaymin Shah &…
Read the full analysis - Scrutinizer Reports Confirm Passage of All Resolutions at 2026 AGM with Over 99% Votes in FavorAGM/EGMhigh impact
Cruxal's analysis: The scrutinizer reports for Ishita Drugs & Industries Ltd.'s 2026 AGM reveal that all…
Read the full analysis - Ishita Drugs & Industries Limited holds AGM; no immediate financial disclosures or strategic events announcedAGM/EGMlow impact
Cruxal's analysis: Ishita Drugs & Industries Limited conducted its 33rd Annual General Meeting on 30th…
Read the full analysis - The trading window for dealing in securities of the company by designated persons stands closed from Thursday, 01st Octomber, 2026 till 48 hours after the declaration of the Unaudited Financial ....Insider Trading / SASTlow impact
- Ishita Drugs & Industries Ltd enters into a loan agreement with HDFC Bank LimitedCompany Updatelow impact
Cruxal's analysis: Ishita Drugs and Industries Limited has formally entered into a loan agreement with HDFC…
Read the full analysis - Ishita Drugs and Industries Limited approves new debt facility of 11.75 crore from HDFC BankBoard Meetingmedium impact
Cruxal's analysis: Ishita Drugs and Industries Limited has announced the approval of a new credit facility…
Read the full analysis - Ishita Drugs and Industries Ltd. Announces Board Meeting to Consider Raising Working Capital and Project Term Loan FacilitiesBoard Meetingmedium impact
Cruxal's analysis: Ishita Drugs and Industries Ltd. has scheduled a board meeting for September 22, 2026, to…
Read the full analysis - Ishita Drugs & Industries Ltd issues notice for FY 2025-26 Annual Report accessCompany Updatelow impact
Cruxal's analysis: Ishita Drugs & Industries Ltd has issued a notification to shareholders who have not…
Read the full analysis - Ishita Drugs & Industries Ltd releases FY 2025-26 Annual Report and schedules 33rd AGM for September 30, 2026Otherslow impact
Cruxal's analysis: Ishita Drugs & Industries Ltd has filed its Annual Report for the financial year 2025-26…
Read the full analysis - Ishita Drugs and Industries Ltd. Announces 33rd Annual General Meeting for September 30, 2026AGM/EGMlow impact
Cruxal's analysis: Ishita Drugs and Industries Ltd. has issued a notice for its 33rd Annual General Meeting…
Read the full analysis - Ishita Drugs and Industries Limited schedules Annual General Meeting for September 30, 2026AGM/EGMlow impact
Cruxal's analysis: Ishita Drugs and Industries Limited has announced the scheduling of its Annual General…
Read the full analysis - Ishita Drugs and Industries Limited announces 33rd Annual General Meeting and Book Closure datesCorp. Actionlow impact
Cruxal's analysis: Ishita Drugs and Industries Limited has formally intimated the BSE regarding its 33rd…
Read the full analysis - Ishita Drugs & Industries reports Q1 FY27 results with revenue decline and provides update on manufacturing facility expansionBoard Meetingmedium impact
Cruxal's analysis: Ishita Drugs & Industries Limited reported a decline in revenue from operations to 3.15…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.